Shield Therapeutics plc
("Shield" or the "Company")
Change of accounting reference date and notification of maiden annual results
London, UK, 23 March 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces it has changed its accounting reference date from 30 September to 31 December in accordance with its pre Admission Schedule 1 notice.
The Company will report its audited annual accounts for a twelve month period to 31 December 2015 on 14 June 2016.
Thereafter, interim and annual reports will be published each year for the six months to 30 June and 12 months to 31 December in accordance with the AIM Rules.
For further information please contact:
Shield Therapeutics plc |
+44 (0)191 511 8507 |
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer |
|
|
|
NOMAD Liberum Capital Limited Christopher Britton Steve Pearce Jamil Miah |
+44 (0)20 3100 2222 |
Financial PR Advisor Consilium Strategic Communications |
+44 (0)203 709 5700 [email protected] |
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys |
|
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company's key products are Feraccru and PT20, two late-stage pharmaceuticals for the treatment of iron deficiency anaemia (IDA) and systemic phosphate accumulation (otherwise known as hyperphosphatemia), respectively. Ferracru has recently been granted marketing authorisation across all member states from the European Commission. Shield joined AIM in February 2016 under the ticker STX. For more information please visit www.shieldtherapeutics.com.
